Followers | 46 |
Posts | 4446 |
Boards Moderated | 0 |
Alias Born | 07/26/2010 |
Wednesday, July 30, 2014 9:27:17 AM
Purified Poloxamer 188 (MST-188)
MST-188 (Mast Therapeutics, Inc.) is an investigational agent with potential utility in a
wide range of diseases that are characterized by impaired blood flow. The active ingredient
in MST-188 is a purified form of poloxamer 188. Research has shown that poloxamer 188
lowers blood viscosity, decreases red blood cell aggregation, and decreases friction between red blood cells and vessel walls to increase microvascular blood flow and decrease cell
injury. While it has mostly been studied as a potential treatment for sickle cell disease, it
may also have potential to treat Scleroderma by reducing red blood cell aggregation,
inflammation, and restoring cell membrane integrity. A Phase 3 study of MST-188 in sickle
cell disease is currently underway (May 2014).
Poloxamer 188 is considered safe and is widely used in many over the counter products
such as toothpaste, laxatives, and mouthwash. The FDA approved it more than 50 years
ago as a therapeutic reagent to reduce viscosity of blood before it is used in transfusions.
Bantec Reports an Over 50 Percent Increase in Sales and Profits in Q1 2024 from Q1 2023 • BANT • Apr 25, 2024 10:00 AM
Cannabix's Breath Logix Alcohol Device Delivers Positive Impact to Private Monitoring Agency in Montana, USA • BLO • Apr 25, 2024 8:52 AM
Kona Gold Beverages, Inc. Announces Name Change to NuVibe, Inc. and Initiation of Ticker Symbol Application Process • KGKG • Apr 25, 2024 8:30 AM
Axis Technologies Group and Carbonis Forge Ahead with New Digital Carbon Credit Technology • AXTG • Apr 24, 2024 3:00 AM
North Bay Resources Announces Successful Equipment Test at Bishop Gold Mill, Inyo County, California • NBRI • Apr 23, 2024 9:41 AM
Epazz, Inc.: CryObo, Inc. solar Bitcoin operations will issue tokens • EPAZ • Apr 23, 2024 9:20 AM